Skip to main content
Nano Dimension explores pivot away from AM via Infinite Epigenetics merger
Acquisition
2 min read

Nano Dimension explores pivot away from AM via Infinite Epigenetics merger

Nano Dimension Ltd.
Nano Dimension Ltd.

Hardware

Originally reported by TCT Magazine

Nano Dimension has entered a non-binding agreement to merge with Infinite Epigenetics, an AI-powered preventive health and diagnostics company, in a deal valued at up to $890 million. Under the term sheet, Nano Dimension would acquire 100% of Infinite Epigenetics equity, with the combined entity operating under the Infinite Epigenetics name and trading on Nasdaq under ticker IEAI. The proposed merger follows a multi-month strategic review of approximately 20 companies across multiple sectors, and comes after Nano Dimension divested its Additively Manufactured Electronics business, sold Fabrica and Markforged, and saw Desktop Metal file for bankruptcy over the past 12 months. Existing Nano shareholders would retain meaningful minority ownership and receive a 20% premium to estimated net cash at closing, with the combined company expected to hold over $400 million in cash.

This move represents a near-complete exit from additive manufacturing for a company that once positioned itself as a consolidator across electronics printing, polymer AM, and metal AM. The pattern fits the SPAC-era aftermath: Nano Dimension went public via a reverse merger in 2021, raised substantial capital, and pursued an acquisition-heavy strategy that failed to generate sustainable revenue growth or operational integration. The pivot into healthcare AI diagnostics reflects a management judgment that Nano's remaining cash and Nasdaq listing are more valuable as a public-company shell for a non-AM growth business than as continued investment in AM hardware and materials. The divestiture sequence - selling off the core AME business, exiting Markforged and Fabrica, and watching Desktop Metal collapse - effectively unwinds the consolidation thesis that defined Nano Dimension's 2021-2024 strategy.

From an AM industry perspective, this is a case study in capital allocation risk rather than a signal about AM market health. Nano Dimension's struggles were company-specific: an overcapitalized SPAC vehicle that acquired multiple businesses without achieving operational synergies or market traction. The remaining question is whether any of the divested assets - particularly the AME technology for printed electronics - find a productive home under new ownership, or whether they follow Desktop Metal into restructuring. For AM investors and suppliers, the lesson is that public-company exits from the sector can be orderly and value-preserving for shareholders, even when the underlying technology thesis did not pan out.

Topics

Nano DimensionInfinite Epigeneticsadditive manufacturingmergerhealthcare AINasdaqDesktop MetalMarkforged

How This Connects

6 related events
  1. Same pattern

    AMAA 2026: Safran Scales Additive Manufacturing Across Flight-Critical Engine Parts

  2. Same pattern

    Edgewing secures £4.6bn contract for GCAP sixth-generation fighter design phase

  3. This article

    Nano Dimension explores pivot away from AM via Infinite Epigenetics merger

  4. Company story

    Nano Dimension sells Markforged to Stratasys for $42.5M, two years after $116M acquisition

  5. Same pattern

    SpaceX IPO values company at $1.77 trillion, highlighting its role as a major additive manufacturing user

  6. Same pattern

    FLEETWERX and NPS CAMRE field test distributed AM pipeline for military operations at Camp Roberts

  7. Company story

    Nano Dimension has expanded its strategic partnership with Phillips Corporation to accelerate the adoption of its industrial additive manufacturing platforms across the Southeast United States.